Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
The study seeks to provide long-term follow-up and/or to offer continued maintenance thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be followed until withdrawal of consent, or death.
Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma
DRUG: Thalidomide
Progression-free Survival (PFS), PFS is defined as the length of time, during and after treatment, until documented disease progression or death (by any cause, in the absence of progression)., Up to five years
Overall Survival (OS), OS is defined as the elapsed time from start of treatment until death or date of censoring., Up to five years|Response Rate (RR), Response rate is defined as the percentage of participants whose cancer shrinks or disappears after treatment., Up to five years|Percentage of Participants Experiencing Treatment-Emergent Adverse Events, Treatment emergent adverse events will be assessed by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0., Up to five years
The study seeks to provide long-term follow-up and/or to offer continued maintenance thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be followed until withdrawal of consent, or death.